Compugen - Stock Price History | CGEN

Historical daily share price chart and data for Compugen since 2021 adjusted for splits. The latest closing stock price for Compugen as of September 27, 2021 is 6.22.
  • The all-time high Compugen stock closing price was 19.45 on August 25, 2020.
  • The Compugen 52-week high stock price is 18.75, which is 201.4% above the current share price.
  • The Compugen 52-week low stock price is 5.76, which is 7.4% below the current share price.
  • The average Compugen stock price for the last 52 weeks is 9.99.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Compugen Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 12.9209 6.1200 19.4500 5.7900 12.1100 103.19%
2019 3.9718 2.3500 6.1600 2.3500 5.9600 174.65%
2018 3.4497 2.7000 4.7000 2.1700 2.1700 -13.20%
2017 3.8024 5.1000 5.3500 2.3500 2.5000 -50.98%
2016 6.1753 6.4300 7.4100 4.5000 5.1000 -20.19%
2015 6.8758 8.6000 9.3900 4.7800 6.3900 -23.29%
2014 9.1214 8.9600 14.2000 6.4400 8.3300 -6.93%
2013 7.1682 5.0100 11.2700 4.6600 8.9500 81.91%
2012 4.5136 5.1300 6.2500 3.0500 4.9200 -0.61%
2011 4.4772 5.0300 5.7400 3.5000 4.9500 0.61%
2010 4.3698 4.7700 5.2500 3.1500 4.9200 1.44%
2009 1.7829 0.4200 5.2000 0.4000 4.8500 1027.91%
2008 1.8763 1.6900 2.7500 0.3850 0.4300 -73.13%
2007 2.5590 2.6800 3.0994 1.6000 1.6000 -38.22%
2006 3.3749 4.5300 5.2000 2.3700 2.5900 -39.20%
2005 3.6949 5.3500 6.4000 2.5400 4.2600 -17.28%
2004 5.4484 5.0500 7.9000 3.2100 5.1500 1.98%
2003 3.9074 1.8500 5.9100 1.5500 5.0500 185.31%
2002 2.3774 4.3500 5.0400 0.9500 1.7700 -62.34%
2001 4.2776 5.6250 7.8750 2.6200 4.7000 -24.80%
2000 10.6846 11.1200 18.3600 5.3130 6.2500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.426B $0.002B
Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29